Senetek
This article was originally published in The Rose Sheet
Executive Summary
First quarter sales jumped 80% to $1.8 mil. due to higher skin care sales and licensing royalties, Kinetin manufacturer says. Company records a net loss of $593,000 compared to deficit of $1.4 mil. in prior-year period. Effort to focus on high-margin royalty income received from licenses led to improved results, Napa, Calif. firm maintains. Senetek licenses its Kinetin technology to Revlon and The Body Shop among other firms
|
First quarter sales jumped 80% to $1.8 mil. due to higher skin care sales and licensing royalties, Kinetin manufacturer says. Company records a net loss of $593,000 compared to deficit of $1.4 mil. in prior-year period. Effort to focus on high-margin royalty income received from licenses led to improved results, Napa, Calif. firm maintains. Senetek licenses its Kinetin technology to Revlon and The Body Shop among other firms. |